Melanoma Brain Metastases: Is It Time to Reassess the Bias?

Current Problems in Cancer

Volumn 35, Issue 4, 2011, Pages 200-210

  Flanigan, Jaclyn C ^a   Jilaveanu, Lucia B ^a   Faries, Mark ^a   Sznol, Mario ^a   Ariyan, Stephan ^a   Yu, James B ^a   Knisely, Jonathan P S ^a   Chiang, Veronica L ^a   Kluger, Harriet M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; GSK 2118436; IPILIMUMAB; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; ASYMPTOMATIC DISEASE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN METASTASIS; BRAIN SURGERY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INFORMATION RETRIEVAL; MELANOMA; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PROGNOSIS; STEREOTACTIC RADIOSURGERY;

ADULT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 80052684940     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2011.07.003     Document Type: Article

References (40)

1. Sloan A.E., Nock C.J., Einstein D.B. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 2009, 16:248-255.
2. Tsao H., Atkins M.B., Sober A.J. Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012.
3. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
4. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
5. Sampson J.H., Carter J.H., Friedman A.H., et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998, 88:11-20.
6. Retsas S., Gershuny A.R. Central nervous system involvement in malignant melanoma. Cancer 1988, 61:1926-1934.
7. de la Monte S.M., Moore G.W., Hutchins G.M. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983, 43:3427-3433.
8. Amer M.H., Al-Sarraf M., Baker L.H., et al. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978, 42:660-668.
9. Davies M.A., Liu P., McIntyre S., et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011, 117:1687-1696.
10. Staudt M., Lasithiotakis K., Leiter U., et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010, 102:1213-1218.
11. Schellinger P.D., Meinck H.M., Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neuro Oncol 1999, 44:275-281.
12. Davis P.C., Hudgins P.A., Peterman S.B., et al. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991, 12:293-300.
13. Patnana M., Bronstein Y., Szklaruk J., et al. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 2011, 66:224-236.
14. Chang E.L., Hassenbusch S.J., Shiu A.S., et al. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 2003, 53:272-280. [Discussion 280-1].
15. Mathieu D., Kondziolka D., Cooper P.B., et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg 2007, 54:241-247.
16. Eigentler T.K., Figl A., Krex D., et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011, 117:1697-1703.
17. Lonser R.R., Song D.K., Klapper J., et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg 2011, 115:30-36.
18. Provenzale J.M., Mukundan S., Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol 2005, 185:763-767.
19. Margolin K.A., Di Giacomo A.M., Maio M. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Semin Oncol 2010, 37:468-472.
20. Schartz N.E., Farges C., Madelaine I., et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010, 20:247-250.
21. Lawrence D.P., Hamid O., McDermott D.F., et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. J Clin Oncol 2010, 28(suppl):15s. (abstract 8523).
22. Amaravadi R.K., Schuchter L.M., McDermott D.F., et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Cancer Res 2009, 15:7711-7718.
23. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95:581-586.
24. Lorigan P., Corrie P., Chao D., et al. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J Clin Oncol 2006, 24(18)(suppl):8012.
25. Agarwala S.S., Reyderman L., Statkevich P. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol 1998, 9(suppl 4):138. (abstract 659a).
26. Agarwala S.S., Kirkwood J.M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000, 5:144-151.
27. Schadendorf D., Hauschild A., Ugurel S., et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol 2006, 17:1592-1597.
28. Long G.V., Kefford R.F., Carr P.J.A., et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets). Ann Oncol 2010, 21(suppl 8):viii12.
29. Moriyama B., Torabi-Parizi P., Pratt A.K., et al. Pharmacokinetics of liposomal amphotericin B in pleural fluid. Antimicrob Agents Chemother 2010, 54:1633-1635.
30. Weiler S., Bellmann-Weiler R., Joannidis M., et al. Penetration of amphotericin B lipid formulations into pleural effusion. Antimicrob Agents Chemother 2007, 51:4211-4213.
31. Elliott A.M., Berning S.E., Iseman M.D., et al. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis 1995, 76:463-467.
32. Jutte P.C., Rutgers S.R., Van Altena R., et al. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. Int J Tuberc Lung Dis 2004, 8:1368-1372.
33. Liao W.C., Chen C.H., Tu C.Y. Black pleural effusion in melanoma. CMAJ 2010, 182:E314.
34. Mohan K.M., Gowrinath K. Unusual thoracic manifestation of metastatic malignant melanoma. Lung 2010, 27:96-98.
35. Kiser A.C., Egan T.M. Metastatic melanoma to the pleural space. Ann Thorac Surg 2002, 74:1257.
36. Burrows C.M., Mathews W.C., Colt H.G. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000, 117:73-78.
37. Ozyurtkan M.O., Balci A.E., Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med 2010, 21:30-34.
38. Heffner J.E., Klein J.S. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008, 83:235-250.
39. Boogerd W., de Gast G.C., Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?. Cancer 2007, 109:306-312.
40. Agarwala S.S., Kirkwood J.M., Gore M., et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004, 22:2101-2107.